Squarepoint’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Squarepoint's VRTX Position: Q2 2026 in Review
Squarepoint increased its Vertex Pharmaceuticals (VRTX) stake by 78% in Q2 2026, buying an estimated $2.34M and bringing the position to 12,031 shares worth $5.98M. The position accounts for 0.01% of the portfolio, ranked #1455.
Squarepoint first reported a position in VRTX in Q2 2015 and has held it in 37 quarters since. The position peaked at $238M in Q3 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Squarepoint held 12,031 shares of Vertex Pharmaceuticals worth $5.98M as of Q2 2026.
- Squarepoint bought 5,279 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.34M.
- Vertex Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1455 holding.
- Squarepoint first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 37 quarters since.
- Squarepoint's Vertex Pharmaceuticals position peaked at $238M in Q3 2025.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.